2.1K(top 0.1%)
papers
109.3K(top 0.1%)
citations
161(top 0.1%)
h-index
277(top 0.1%)
g-index
2.2K
all documents
118.5K
doc citations
6.6K
citing journals

Top Articles

#TitleJournalYearCitations
1Lung cancer: current therapies and new targeted treatmentsLancet, The20172,267
2Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trialLancet, The20042,248
3Nutrition and physical activity guidelines for cancer survivorsCa-A Cancer Journal for Clinicians20121,600
4Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung CancerJournal of the National Cancer Institute20051,517
5Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 studyLancet Oncology, The20151,100
6Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trialLancet Oncology, The20181,089
7PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison ProjectJournal of Thoracic Oncology20171,067
8American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Prevention: Reducing the Risk of Cancer With Healthy Food Choices and Physical ActivityCa-A Cancer Journal for Clinicians20061,021
9Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the BrainNew England Journal of Medicine2018983
10Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2019943
11HER2 in gastric cancer: a new prognostic factor and a novel therapeutic targetAnnals of Oncology2008931
12Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancerNature Genetics2012906
13Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2020848
14Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisLancet Oncology, The2011847
15Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registryAnnals of Oncology2019842
16Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous LeukemiaCancer Discovery2016799
17Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2017762
18Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2016760
19Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2021758
20Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology2006701
21Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung CancerNew England Journal of Medicine2018691
22Molecular Testing for Mutations in Improving the Fine-Needle Aspiration Diagnosis of Thyroid NodulesJournal of Clinical Endocrinology and Metabolism2009674
23Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2019672
24Nutrition and Physical Activity During and After Cancer Treatment: An American Cancer Society Guide for Informed ChoicesCa-A Cancer Journal for Clinicians2006649
25Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)Cancer Discovery2017647
26Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort studyLancet Oncology, The2016607
27Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung CancerJournal of Thoracic Oncology2012585
28Localization of Bronchial Intraepithelial Neoplastic Lesions by Fluorescence BronchoscopyChest1998565
29Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2021564
30Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2022562
31Small-cell lung cancer: what we know, what we need to know and the path forwardNature Reviews Cancer2017558
32Prostate Cancer, Version 1.2016Journal of the National Comprehensive Cancer Network: JNCCN2016544
33Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody CetuximabScience Translational Medicine2011543
34Interrogating open issues in cancer precision medicine with patient-derived xenograftsNature Reviews Cancer2017527
35Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancerNature Medicine2013526
36Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapyBlood2013524
37Deoxyribonucleic Acid Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and MisidentificationJournal of Clinical Endocrinology and Metabolism2008520
38Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trialLancet, The2016512
39Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemiaBlood2010503
40Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2021498
41Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trialLancet Oncology, The2012487
42Restoring E-Cadherin Expression Increases Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Lung Cancer Cell LinesCancer Research2006482
43Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2021477
44Early detection of lung cancer: clinical perspectives of recent advances in biology and radiologyClinical Cancer Research2001468
45Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2017451
46Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced MelanomaJournal of Clinical Oncology2022446
47Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2018432
48Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trialLancet Oncology, The2015431
492015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed?Cancer2017428
50Epidemiology of prostate cancerUrology2003421